The company has multiple product candidates in clinical development in central nervous system indications, including post-traumatic stress disorder, cognitive impairment associated, and opioid use disorder. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Poster Presentation: Tuesday, November 15, 2022, 4:00 PM PTĪptinyx Inc. Presentation Title: Preclinical evaluation of the NMDAR positive allosteric modulator NYX-783 for opioid use disorder (Poster Number: 561.05) Poster Presentation: Tuesday, November 15, 2022, 1:00 PM PT Presenter: Joanna Dabrowska, Ph.D., PharmD (Rosalind Franklin University of Medicine and Science) Presentation Title: Positive allosteric modulator of the NMDA receptor, NYX-783, reverses repeated stress-induced reduction of exploration and reduces fear to unpredictable threats in rats (Poster Number: 560.01)
0 Comments
Leave a Reply. |